Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsNewsAboutContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

News

Erenumab

(Aimovig®)

Aimovig®

Drug updated on 3/28/2024

Dosage FormInjection (subcutaneous; 70 mg/mL, 140 mg/mL)
Drug ClassCalcitonin gene-related peptide receptor antagonists
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated for the preventive treatment of migraine in adults.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Erenumab (Aimovig) is indicated for the preventive treatment of migraine in adults.
  • A total of 24 systematic reviews and meta-analyses were reviewed, providing information on erenumab's efficacy, safety profile, comparison with other drugs targeting the calcitonin gene-related peptide (CGRP) pathway for migraine prevention.
  • Erenumab has shown significant efficacy in both short-term and long-term treatment of episodic and chronic migraines across various subtypes including allodynia, aura, prior preventive therapy failure, medication overuse headache and menstrual migraine.
  • Compared to other CGRP-targeting drugs such as eptinezumab, fremanezumab galcanezumab and gepants; erenumab alongside fremanezumab showed a lower odds of adverse events indicating a favorable safety profile while maintaining effectiveness in reducing mean monthly migraine days compared to placebo.
  • The drug was well-tolerated with low incidences of serious adverse events making it safe for long term use; common side effects included injection site reactions and constipation but these were generally mild leading to low discontinuation rates due to adverse events.
  • Observational cohort studies have reinforced findings from randomized controlled trials showing that erenumub along with other CGRP inhibitors are effective not only under trial conditions but also real-world settings by significantly reducing monthly migraine days improving quality life indicators among patients suffering from migraines.
  • There is an identified gap regarding sex-based differences in responses despite high proportion women participating clinical trials few studies analyzed results separately by sex which could be crucial understanding how different populations respond this treatment.
  • Erenumb offers balance between efficacy safety rapid onset effect applicability diverse patient population however more research especially head-to-head trials focusing specific subgroups would further elucidate its comparative effectiveness.

Product Monograph / Prescribing Information

Document TitleYearSource
Aimovig (erenumab) Prescribing Information.2023Amgen Inc., Thousand Oaks, CA

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis.2023Cephalalgia: International Headache Society
Erenumab efficacy in migraine headache prophylaxis: A systematic review.2023International immunopharmacology
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.2023Cephalalgia: International Headache Society
Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review. 2023Cureus
Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies. 2023Clinical Drug Investigation
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review. 2023Journal of Headache and Pain
Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis. 2023The Clinical Journal of Pain
Gender bias in clinical trials of biological agents for migraine: A systematic review. 2023PLoS One
Erenumab efficacy in migraine headache prophylaxis: A systematic review. 2023International Immunopharmacology
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. 2022The Journal of Headache and Pain
A systematic review of economic evaluations of pharmacological treatments for adults with chronic migraine.2022The Journal of Headache and Pain
Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review.2022European Journal of Medical Research
Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials.2022Headache: The Journal of Head and Face Pain
Long-term safety and effectiveness of erenumab in patients with migraine: a systematic review and single-arm meta-analysis.2022Clinical Drug Investigation
A systematic review, meta-analysis and meta-regression evaluating the adverse reactions to erenumab in the preventive treatment of migraine. 2021Expert Opinion on Drug Safety
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine: a systematic review and network meta-analysis. 2021Frontiers in Pharmacology
Safety and tolerability evaluation of erenumab for the preventive treatment of migraine. 2021Expert Opinion on Drug Safety
Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. 2021Cephalalgia
Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: a systematic review and network meta-analysis.2021Clinical Neurology and Neurosurgery
Comparative effectiveness and tolerability of the pharmacology of monoclonal antibodies targeting the calcitonin gene‑related peptide and its receptor for the prevention of chronic migraine: a network meta‑analysis of randomized controlled trials.2021Neurotherapeutics
Indirect comparison of topiramate and monoclonal antibodies against CGRP or its receptor for the prophylaxis of episodic migraine: a systematic review with meta analysis.2021CNS Drugs
Clinical review report: erenumab (Aimovig).2020CADTH
Erenumab for preventive treatment of migraine: a systematic review and meta-analysis of efficacy and safety.2019Drugs
Erenumab safety and efficacy in migraine: a systematic review and meta-analysis of randomized clinical trials.2019Medicine
CGRP, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data.2019Cephalalgia
Assessment report: Aimovig. 2018EMA
Calcitonin gene-related peptide (CGRP) inhibitors as preventive treatments for patients with episodic or chronic migraine: effectiveness and value. 2018ICER

Clinical Practice Guidelines

Document TitleYearSource
European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update.2022The Journal of Headache and Pain
The primary care management of headache: synopsis of the 2020 U.S. department of veterans affairs and U.S. department of defense clinical practice guideline.2022Military Medicine